CXCR5+ CD8 T cells displayed higher activation potential despite high PD-1 expression, in tumor-involved lymph nodes from patients with thyroid cancer

The Immune Landscape of Thyroid Cancer in the Context of Immune Checkpoint Inhibition

“…The latter findings suggest a BRAF-driven tumor-promoting microenvironment [204]. A recent study evaluated the CXCR5 + CD8 + T cell subset in peripheral blood, tumor-draining lymph nodes (TDLNs), and tumors from TC patients [205]. Although CXCR5 + CD8 + T cells expressed higher PD-1, T-cell immunoglobulin and mucin-domain containing-3 (TIM-3), and Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4) markers than CXCR5 − CD8 + T cells, these cells displayed a higher expression of cytotoxic molecules (e.g., granzymes and perforin).…”

Intratumoral CXCR5+CD8+T associates with favorable clinical outcomes and immunogenic contexture in gastric cancer

“…Several studies have identified a subset of CD8 + T that is characterized by the expression of CXCR5 in chronic lymphocytic choriomeningitis virus infection, which serves as a self-renewing exhausted progenitor and provides proliferation burst after programmed cell death protein 1 (PD-1) blockade 6 – 8 . Further studies have reported that the frequent density of CXCR5 + CD8 + T is associated with better OS in patients with lymphoma 9 , liver 10 , pancreas 11 , lung 12 , colorectum 13 , and thyroid 14 malignancies. However, the prognostic value and the potential therapeutic benefits of targeting CXCR5 + CD8 + T in GC have not been explored.…”

Identification and validation of an excellent prognosis subtype of muscle-invasive bladder cancer patients with intratumoral CXCR5 + CD8 + T cell abundance

“…18 In HBV-related liver cancer, CXCR5 + CD8 + T cells are likely to be initially induced by viral responses, and then act on tumor cells. 19 As it is demonstrated in previous studies, CXCR5 + CD8 + T cell frequency is positively correlated with the overall survival of patients with various malignancies, including the malignancies mentioned above along with colorectal, 20 pancreas, 21 lung 22 and thyroid 23 cancer. Intriguingly, a study revealed that CXCR5 + CD8 + T cells provide a proliferation burst after PD-1 blockade in LCMV infection, suggesting its sensitivity to anti-PD-1 therapy.…”

“…Intriguingly, we found CXCR5 + CD8 + T cells could serve as a more powerful prognosticator than CD8 + T cells in MIBC, which was in line with its impressive anti-tumor function as discovered in other tumor types. [18][19][20][21][22][23] We have previously reported several immune cells infiltration associated with ACT benefit in MIBC, such as tumor-infiltrating neutrophils, mast cells, B cells, and IL-22 + cell. 25,[31][32][33][34] Remarkably, we revealed the outstanding predictive ability of CXCR5 + CD8 + T cells in response to ACT in MIBC.…”